Posted 25th August 2017 by Jane Williams
Rheumatoid arthritis is one of the highest sources of the inefficiency of worldwide health care systems. This could be avoided by more tailored and individualised therapeutic strategies which require better molecular characterization of each patient.
Posted 7th August 2017 by Jane Williams
At the dawn of the last century, people who were heralded as world-changers were a different breed. Edison, Franklin (and let’s also put Tesla here, though his contributions weren’t recognized at the time), Turing, Neumann, and a lot of other great people. Things are different now. The people we idolize today are the innovators – Jobs, Musk, Page&Brin – the Great Communicators who can drive products to the market, and carve out a viable market strategy despite the strong competition, or create entirely new markets.
Posted 17th July 2017 by Jane Williams
In recent times, we have seen advances in precision medicine lead to powerful discoveries and improved patient care. Liquid biopsies for example, now have the potential to be a real game-changer in cancer testing and could revolutionise cancer care.
Posted 12th July 2017 by Jane Williams
With so many promising cancer therapies emerging from research labs, a key challenge for biomedical researchers is to develop tools that accurately predict treatment efficacy against a patient’s specific cancer, thereby avoiding subjecting the patient to a trial and error process to find the best drug.
Posted 7th June 2017 by Jane Williams
Unreasonable cost of trial-and-error medicine means precision medicine is imperative for targeted therapies
Rising pressures to decrease healthcare cost globally, the emergence of value-based reimbursement models and healthcare digitisation trends are transitioning the medication model from ‘one-size-fits-all’ to stratified and outcome based targeted therapies.
Posted 8th May 2017 by Jane Williams
Future of immunotherapies
Immunotherapies are on the fast growth trajectory which will be moderated based on responder groups, toxicity and efficacy results and high costs and increasingly used in combination therapies. The overall immune oncology checkpoint inhibitor market was over $2.0 billion and is set to grow to $14 billion by 2018.
Posted 20th February 2017 by Jane Williams
Jim Huggett’s research focuses on molecular diagnostics, genomics and nucleic acids, including cancer and foetal genetic analysis and the diagnosis of infectious diseases. We interviewed him about the latest developments and the latest advances in qPCR research.
Posted 17th February 2017 by Jane Williams
President Jimmy Carter announced last spring that he no longer needed treatments for the metastatic melanoma found in his brain – after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer detect the cancer.